TABLE 5.
Immunogenicity of pneumococcal conjugate vaccine in older adults
| Study | Subjectsa | Series | Antibody to CP after PCV |
|---|---|---|---|
| Powers et al. (111) | n = 23; mean age, 67 yr (23 age-matched controls) | 5-valent CRM197b and then PPV after 6 mo (23 controls received PPV and then placebo at mo 6) | Similar % with 2 FI at mo 1 and 6 except lower for 1/5 serotypes (19F) at mo 6 in PCV group; in PCV subjects, minimal response except to 19F after mo 6 in PPV group |
| Shelly et al. (134) | n = 49; median age, 66 yr (healthy, young controls) | 5-valent CRM197 and then PPV at mo 2 (controls received PPV and then placebo at mo 2) | Response same for type 6B; lower for type 14 in PCV group than in control group; only 1.2 FI in PCV group after mo 2 post-PPV; IgA by nasal secretion unchanged after vaccination |
| Lottenbach et al. (73) | n = 12; age, 50-85 yrc (12 age-matched controls) | 5-valent CRM197 (controls received PPV) | Older adults appear to have antibody response to one PPV similar to that to one PCV (no statistical analysis) |
a
Controls are the group to which older subjects receiving PCV are being compared (not necessarily specified as control by investigators).
b
CRM197, mutant diphtheria toxin conjugated to pneumococcal polysaccharides.
c
No mean provided.